• Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
463
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
11
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. SIMEPREVIR Presented By : P.Harsha Vardhan Reddy, PharmD-IV Year.
  • 2. INTRODUCTION • Brand Name : Olysio • Approved Date : Nov. 22, 2013 • Company Name : Janssen Therapeutics • Drug Category : Shedule-H • Pharmacologic Drug Category : NS3/4A Protease Inhibitor • Pregnancy Category : X Olysio™ is The First Once-daily Protease Inhibitor Approved For The Treatment Of Chronic Hepatitis C In A Combination Antiviral Regimen For Adults With Compensated Liver Disease.
  • 3. INDICATION : • OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. • OLYSIO efficacy has been established in combination with peginterferon-alfa and ribavirin (P/R), in HCV genotype 1 (G1) infected subjects with compensated liver disease (including cirrhosis). • The following points should be considered when initiating OLYSIO for treatment of CHC infection: • OLYSIO must not be used as monotherapy. • OLYSIO efficacy in combination with P/R is influenced by baseline host and viral factors. • OLYSIO efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes OLYSIO or other HCV protease inhibitors.
  • 4. DOSAGE AND ADMINISTRATION : • One 150 Mg Capsule Taken Once Daily With Food. • Olysio Should Be Administered With Both Peginterferon Alfa And Ribavirin. The Recommended Treatment Duration Of OLYSIO With Peginterferon Alfa And Ribavirin Is 12 Weeks, Followed By Either 12 Or 36 Additional Weeks Of Peginterferon Alfa And Ribavirin Depending On Prior Response Status. • A Dose Recommendation Cannot Be Made For Patients Of East Asian Ancestry. • A Dose Recommendation Cannot Be Made For Patients With Moderate To Severe Hepatic Impairment.
  • 5. DOSAGE FORMS & STRENGTHS : • Capsule: 150 mg CONTRAINDICATIONS : • All contraindications to peginterferon alfa and ribavirin also apply to OLYSIO combination treatment with peginterferon alfa and ribavirin. • Because ribavirin may cause birth defects and fetal death, OLYSIO in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant.
  • 6. WARNINGS AND PRECAUTIONS : Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death and animal studies have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy, use at least two effective methods of contraception during treatment, and undergo monthly pregnancy tests. Photosensitivity: Serious photosensitivity reactions have been observed during combination therapy with OLYSIO, peginterferon alfa and ribavirin. Use sun protection measures and limit sun exposure. Consider discontinuation if a photosensitivity reaction occurs. Rash: Rash has been observed during combination therapy with OLYSIO, peginterferon alfa and ribavirin. Discontinue OLYSIO if severe rash occurs.
  • 7. ADVERSE REACTIONS : • The most common reported adverse reactions (greater than 20% of subjects) in subjects receiving the combination of OLYSIO with peginterferon and ribavirin during the first 12 weeks of treatment were: rash (including photosensitivity), pruritus and nausea. To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP at 1800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • 8. DRUG INTERACTIONS : • Co-administration of OLYSIO with drugs that are moderate or strong inducers or inhibitors of CYP3A may significantly affect the plasma concentrations of simeprevir. The potential for drug-drug interactions must be considered prior to and during treatment.
  • 9. Thank You…